Eintrag weiter verarbeiten
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial
Gespeichert in:
| Zeitschriftentitel: | International Journal of Cancer |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| In: | International Journal of Cancer, 145, 2019, 3, S. 857-868 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Janning, Melanie Müller, Volkmar Vettorazzi, Eik Cubas‐Cordova, Miguel Gensch, Victoria Ben‐Batalla, Isabel zu Eulenburg, Christine Schem, Christian Fasching, Peter A. Schnappauf, Benjamin Karn, Thomas Fehm, Tanja Just, Marianne Kühn, Thorsten Holms, Frank Overkamp, Friedrich Krabisch, Petra Rack, Brigitte Denkert, Carsten Untch, Michael Tesch, Hans Rezai, Mahdi Kittel, Kornelia Pantel, Klaus Bokemeyer, Carsten Loibl, Sibylle von Minckwitz, Gunter Loges, Sonja Janning, Melanie Müller, Volkmar Vettorazzi, Eik Cubas‐Cordova, Miguel Gensch, Victoria Ben‐Batalla, Isabel zu Eulenburg, Christine Schem, Christian Fasching, Peter A. Schnappauf, Benjamin Karn, Thomas Fehm, Tanja Just, Marianne Kühn, Thorsten Holms, Frank Overkamp, Friedrich Krabisch, Petra Rack, Brigitte Denkert, Carsten Untch, Michael Tesch, Hans Rezai, Mahdi Kittel, Kornelia Pantel, Klaus Bokemeyer, Carsten Loibl, Sibylle von Minckwitz, Gunter Loges, Sonja |
|---|---|
| author |
Janning, Melanie Müller, Volkmar Vettorazzi, Eik Cubas‐Cordova, Miguel Gensch, Victoria Ben‐Batalla, Isabel zu Eulenburg, Christine Schem, Christian Fasching, Peter A. Schnappauf, Benjamin Karn, Thomas Fehm, Tanja Just, Marianne Kühn, Thorsten Holms, Frank Overkamp, Friedrich Krabisch, Petra Rack, Brigitte Denkert, Carsten Untch, Michael Tesch, Hans Rezai, Mahdi Kittel, Kornelia Pantel, Klaus Bokemeyer, Carsten Loibl, Sibylle von Minckwitz, Gunter Loges, Sonja |
| spellingShingle |
Janning, Melanie Müller, Volkmar Vettorazzi, Eik Cubas‐Cordova, Miguel Gensch, Victoria Ben‐Batalla, Isabel zu Eulenburg, Christine Schem, Christian Fasching, Peter A. Schnappauf, Benjamin Karn, Thomas Fehm, Tanja Just, Marianne Kühn, Thorsten Holms, Frank Overkamp, Friedrich Krabisch, Petra Rack, Brigitte Denkert, Carsten Untch, Michael Tesch, Hans Rezai, Mahdi Kittel, Kornelia Pantel, Klaus Bokemeyer, Carsten Loibl, Sibylle von Minckwitz, Gunter Loges, Sonja International Journal of Cancer Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial Cancer Research Oncology |
| author_sort |
janning, melanie |
| spelling |
Janning, Melanie Müller, Volkmar Vettorazzi, Eik Cubas‐Cordova, Miguel Gensch, Victoria Ben‐Batalla, Isabel zu Eulenburg, Christine Schem, Christian Fasching, Peter A. Schnappauf, Benjamin Karn, Thomas Fehm, Tanja Just, Marianne Kühn, Thorsten Holms, Frank Overkamp, Friedrich Krabisch, Petra Rack, Brigitte Denkert, Carsten Untch, Michael Tesch, Hans Rezai, Mahdi Kittel, Kornelia Pantel, Klaus Bokemeyer, Carsten Loibl, Sibylle von Minckwitz, Gunter Loges, Sonja 0020-7136 1097-0215 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/ijc.32163 <jats:p>We analyzed the predictive potential of pretreatment soluble carbonic anhydrase IX levels (sCAIX) for the efficacy of bevacizumab in the phase III neoadjuvant GeparQuinto trial. sCAIX was determined by enzyme‐linked immunosorbent assay (ELISA). Correlations between sCAIX and pathological complete response (pCR), disease‐free and overall survival (DFS, OS) were assessed with logistic and Cox proportional hazard regression models using bootstrapping for robust estimates and internal validation. 1,160 HER2‐negative patient sera were analyzed, of whom 577 received bevacizumab. Patients with low pretreatment sCAIX had decreased pCR rates (12.1 <jats:italic>vs</jats:italic>. 20.1%, <jats:italic>p</jats:italic> = 0.012) and poorer DFS (adjusted 5‐year DFS 71.4 <jats:italic>vs</jats:italic>. 80.5 months, <jats:italic>p</jats:italic> = 0.010) compared to patients with high sCAIX when treated with neoadjuvant chemotherapy (NCT). For patients with low sCAIX, pCR rates significantly improved upon addition of bevacizumab to NCT (12.1 <jats:italic>vs</jats:italic>. 20.4%; <jats:italic>p</jats:italic> = 0.017), which was not the case in patients with high sCAIX (20.1% for NCT <jats:italic>vs</jats:italic>. 17.0% for NCT‐B, <jats:italic>p</jats:italic> = 0.913). When analyzing DFS we found that bevacizumab improved 5‐year DFS for patients with low sCAIX numerically but not significantly (71.4 <jats:italic>vs</jats:italic>. 78.5 months; log rank 0.234). In contrast, addition of bevacizumab worsened 5‐year DFS for patients with high sCAIX (81 <jats:italic>vs</jats:italic>. 73.6 months, log‐rank 0.025). By assessing sCAIX levels we identified a patient cohort in breast cancer that is potentially undertreated with NCT alone. Bevacizumab improved pCR rates in this group, suggesting sCAIX is a predictive biomarker for bevacizumab with regards to treatment response. Our data also show that bevacizumab is not beneficial in patients with high sCAIX.</jats:p> Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial International Journal of Cancer |
| doi_str_mv |
10.1002/ijc.32163 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMzIxNjM |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMzIxNjM |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Wiley, 2019 |
| imprint_str_mv |
Wiley, 2019 |
| issn |
0020-7136 1097-0215 |
| issn_str_mv |
0020-7136 1097-0215 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
janning2019evaluationofsolublecarbonicanhydraseixaspredictivemarkerforefficacyofbevacizumababiomarkeranalysisfromthegeparquintophaseiiineoadjuvantbreastcancertrial |
| publishDateSort |
2019 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
International Journal of Cancer |
| source_id |
49 |
| title |
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_unstemmed |
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_full |
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_fullStr |
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_full_unstemmed |
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_short |
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_sort |
evaluation of soluble carbonic anhydrase ix as predictive marker for efficacy of bevacizumab: a biomarker analysis from the geparquinto phase iii neoadjuvant breast cancer trial |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1002/ijc.32163 |
| publishDate |
2019 |
| physical |
857-868 |
| description |
<jats:p>We analyzed the predictive potential of pretreatment soluble carbonic anhydrase IX levels (sCAIX) for the efficacy of bevacizumab in the phase III neoadjuvant GeparQuinto trial. sCAIX was determined by enzyme‐linked immunosorbent assay (ELISA). Correlations between sCAIX and pathological complete response (pCR), disease‐free and overall survival (DFS, OS) were assessed with logistic and Cox proportional hazard regression models using bootstrapping for robust estimates and internal validation. 1,160 HER2‐negative patient sera were analyzed, of whom 577 received bevacizumab. Patients with low pretreatment sCAIX had decreased pCR rates (12.1 <jats:italic>vs</jats:italic>. 20.1%, <jats:italic>p</jats:italic> = 0.012) and poorer DFS (adjusted 5‐year DFS 71.4 <jats:italic>vs</jats:italic>. 80.5 months, <jats:italic>p</jats:italic> = 0.010) compared to patients with high sCAIX when treated with neoadjuvant chemotherapy (NCT). For patients with low sCAIX, pCR rates significantly improved upon addition of bevacizumab to NCT (12.1 <jats:italic>vs</jats:italic>. 20.4%; <jats:italic>p</jats:italic> = 0.017), which was not the case in patients with high sCAIX (20.1% for NCT <jats:italic>vs</jats:italic>. 17.0% for NCT‐B, <jats:italic>p</jats:italic> = 0.913). When analyzing DFS we found that bevacizumab improved 5‐year DFS for patients with low sCAIX numerically but not significantly (71.4 <jats:italic>vs</jats:italic>. 78.5 months; log rank 0.234). In contrast, addition of bevacizumab worsened 5‐year DFS for patients with high sCAIX (81 <jats:italic>vs</jats:italic>. 73.6 months, log‐rank 0.025). By assessing sCAIX levels we identified a patient cohort in breast cancer that is potentially undertreated with NCT alone. Bevacizumab improved pCR rates in this group, suggesting sCAIX is a predictive biomarker for bevacizumab with regards to treatment response. Our data also show that bevacizumab is not beneficial in patients with high sCAIX.</jats:p> |
| container_issue |
3 |
| container_start_page |
857 |
| container_title |
International Journal of Cancer |
| container_volume |
145 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792339193365528580 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:44:14.875Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Evaluation+of+soluble+carbonic+anhydrase+IX+as+predictive+marker+for+efficacy+of+bevacizumab%3A+A+biomarker+analysis+from+the+geparquinto+phase+III+neoadjuvant+breast+cancer+trial&rft.date=2019-08-01&genre=article&issn=1097-0215&volume=145&issue=3&spage=857&epage=868&pages=857-868&jtitle=International+Journal+of+Cancer&atitle=Evaluation+of+soluble+carbonic+anhydrase+IX+as+predictive+marker+for+efficacy+of+bevacizumab%3A+A+biomarker+analysis+from+the+geparquinto+phase+III+neoadjuvant+breast+cancer+trial&aulast=Loges&aufirst=Sonja&rft_id=info%3Adoi%2F10.1002%2Fijc.32163&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792339193365528580 |
| author | Janning, Melanie, Müller, Volkmar, Vettorazzi, Eik, Cubas‐Cordova, Miguel, Gensch, Victoria, Ben‐Batalla, Isabel, zu Eulenburg, Christine, Schem, Christian, Fasching, Peter A., Schnappauf, Benjamin, Karn, Thomas, Fehm, Tanja, Just, Marianne, Kühn, Thorsten, Holms, Frank, Overkamp, Friedrich, Krabisch, Petra, Rack, Brigitte, Denkert, Carsten, Untch, Michael, Tesch, Hans, Rezai, Mahdi, Kittel, Kornelia, Pantel, Klaus, Bokemeyer, Carsten, Loibl, Sibylle, von Minckwitz, Gunter, Loges, Sonja |
| author_facet | Janning, Melanie, Müller, Volkmar, Vettorazzi, Eik, Cubas‐Cordova, Miguel, Gensch, Victoria, Ben‐Batalla, Isabel, zu Eulenburg, Christine, Schem, Christian, Fasching, Peter A., Schnappauf, Benjamin, Karn, Thomas, Fehm, Tanja, Just, Marianne, Kühn, Thorsten, Holms, Frank, Overkamp, Friedrich, Krabisch, Petra, Rack, Brigitte, Denkert, Carsten, Untch, Michael, Tesch, Hans, Rezai, Mahdi, Kittel, Kornelia, Pantel, Klaus, Bokemeyer, Carsten, Loibl, Sibylle, von Minckwitz, Gunter, Loges, Sonja, Janning, Melanie, Müller, Volkmar, Vettorazzi, Eik, Cubas‐Cordova, Miguel, Gensch, Victoria, Ben‐Batalla, Isabel, zu Eulenburg, Christine, Schem, Christian, Fasching, Peter A., Schnappauf, Benjamin, Karn, Thomas, Fehm, Tanja, Just, Marianne, Kühn, Thorsten, Holms, Frank, Overkamp, Friedrich, Krabisch, Petra, Rack, Brigitte, Denkert, Carsten, Untch, Michael, Tesch, Hans, Rezai, Mahdi, Kittel, Kornelia, Pantel, Klaus, Bokemeyer, Carsten, Loibl, Sibylle, von Minckwitz, Gunter, Loges, Sonja |
| author_sort | janning, melanie |
| container_issue | 3 |
| container_start_page | 857 |
| container_title | International Journal of Cancer |
| container_volume | 145 |
| description | <jats:p>We analyzed the predictive potential of pretreatment soluble carbonic anhydrase IX levels (sCAIX) for the efficacy of bevacizumab in the phase III neoadjuvant GeparQuinto trial. sCAIX was determined by enzyme‐linked immunosorbent assay (ELISA). Correlations between sCAIX and pathological complete response (pCR), disease‐free and overall survival (DFS, OS) were assessed with logistic and Cox proportional hazard regression models using bootstrapping for robust estimates and internal validation. 1,160 HER2‐negative patient sera were analyzed, of whom 577 received bevacizumab. Patients with low pretreatment sCAIX had decreased pCR rates (12.1 <jats:italic>vs</jats:italic>. 20.1%, <jats:italic>p</jats:italic> = 0.012) and poorer DFS (adjusted 5‐year DFS 71.4 <jats:italic>vs</jats:italic>. 80.5 months, <jats:italic>p</jats:italic> = 0.010) compared to patients with high sCAIX when treated with neoadjuvant chemotherapy (NCT). For patients with low sCAIX, pCR rates significantly improved upon addition of bevacizumab to NCT (12.1 <jats:italic>vs</jats:italic>. 20.4%; <jats:italic>p</jats:italic> = 0.017), which was not the case in patients with high sCAIX (20.1% for NCT <jats:italic>vs</jats:italic>. 17.0% for NCT‐B, <jats:italic>p</jats:italic> = 0.913). When analyzing DFS we found that bevacizumab improved 5‐year DFS for patients with low sCAIX numerically but not significantly (71.4 <jats:italic>vs</jats:italic>. 78.5 months; log rank 0.234). In contrast, addition of bevacizumab worsened 5‐year DFS for patients with high sCAIX (81 <jats:italic>vs</jats:italic>. 73.6 months, log‐rank 0.025). By assessing sCAIX levels we identified a patient cohort in breast cancer that is potentially undertreated with NCT alone. Bevacizumab improved pCR rates in this group, suggesting sCAIX is a predictive biomarker for bevacizumab with regards to treatment response. Our data also show that bevacizumab is not beneficial in patients with high sCAIX.</jats:p> |
| doi_str_mv | 10.1002/ijc.32163 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9pamMuMzIxNjM |
| imprint | Wiley, 2019 |
| imprint_str_mv | Wiley, 2019 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0020-7136, 1097-0215 |
| issn_str_mv | 0020-7136, 1097-0215 |
| language | English |
| last_indexed | 2024-03-01T15:44:14.875Z |
| match_str | janning2019evaluationofsolublecarbonicanhydraseixaspredictivemarkerforefficacyofbevacizumababiomarkeranalysisfromthegeparquintophaseiiineoadjuvantbreastcancertrial |
| mega_collection | Wiley (CrossRef) |
| physical | 857-868 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | International Journal of Cancer |
| source_id | 49 |
| spelling | Janning, Melanie Müller, Volkmar Vettorazzi, Eik Cubas‐Cordova, Miguel Gensch, Victoria Ben‐Batalla, Isabel zu Eulenburg, Christine Schem, Christian Fasching, Peter A. Schnappauf, Benjamin Karn, Thomas Fehm, Tanja Just, Marianne Kühn, Thorsten Holms, Frank Overkamp, Friedrich Krabisch, Petra Rack, Brigitte Denkert, Carsten Untch, Michael Tesch, Hans Rezai, Mahdi Kittel, Kornelia Pantel, Klaus Bokemeyer, Carsten Loibl, Sibylle von Minckwitz, Gunter Loges, Sonja 0020-7136 1097-0215 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/ijc.32163 <jats:p>We analyzed the predictive potential of pretreatment soluble carbonic anhydrase IX levels (sCAIX) for the efficacy of bevacizumab in the phase III neoadjuvant GeparQuinto trial. sCAIX was determined by enzyme‐linked immunosorbent assay (ELISA). Correlations between sCAIX and pathological complete response (pCR), disease‐free and overall survival (DFS, OS) were assessed with logistic and Cox proportional hazard regression models using bootstrapping for robust estimates and internal validation. 1,160 HER2‐negative patient sera were analyzed, of whom 577 received bevacizumab. Patients with low pretreatment sCAIX had decreased pCR rates (12.1 <jats:italic>vs</jats:italic>. 20.1%, <jats:italic>p</jats:italic> = 0.012) and poorer DFS (adjusted 5‐year DFS 71.4 <jats:italic>vs</jats:italic>. 80.5 months, <jats:italic>p</jats:italic> = 0.010) compared to patients with high sCAIX when treated with neoadjuvant chemotherapy (NCT). For patients with low sCAIX, pCR rates significantly improved upon addition of bevacizumab to NCT (12.1 <jats:italic>vs</jats:italic>. 20.4%; <jats:italic>p</jats:italic> = 0.017), which was not the case in patients with high sCAIX (20.1% for NCT <jats:italic>vs</jats:italic>. 17.0% for NCT‐B, <jats:italic>p</jats:italic> = 0.913). When analyzing DFS we found that bevacizumab improved 5‐year DFS for patients with low sCAIX numerically but not significantly (71.4 <jats:italic>vs</jats:italic>. 78.5 months; log rank 0.234). In contrast, addition of bevacizumab worsened 5‐year DFS for patients with high sCAIX (81 <jats:italic>vs</jats:italic>. 73.6 months, log‐rank 0.025). By assessing sCAIX levels we identified a patient cohort in breast cancer that is potentially undertreated with NCT alone. Bevacizumab improved pCR rates in this group, suggesting sCAIX is a predictive biomarker for bevacizumab with regards to treatment response. Our data also show that bevacizumab is not beneficial in patients with high sCAIX.</jats:p> Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial International Journal of Cancer |
| spellingShingle | Janning, Melanie, Müller, Volkmar, Vettorazzi, Eik, Cubas‐Cordova, Miguel, Gensch, Victoria, Ben‐Batalla, Isabel, zu Eulenburg, Christine, Schem, Christian, Fasching, Peter A., Schnappauf, Benjamin, Karn, Thomas, Fehm, Tanja, Just, Marianne, Kühn, Thorsten, Holms, Frank, Overkamp, Friedrich, Krabisch, Petra, Rack, Brigitte, Denkert, Carsten, Untch, Michael, Tesch, Hans, Rezai, Mahdi, Kittel, Kornelia, Pantel, Klaus, Bokemeyer, Carsten, Loibl, Sibylle, von Minckwitz, Gunter, Loges, Sonja, International Journal of Cancer, Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial, Cancer Research, Oncology |
| title | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_full | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_fullStr | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_full_unstemmed | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_short | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| title_sort | evaluation of soluble carbonic anhydrase ix as predictive marker for efficacy of bevacizumab: a biomarker analysis from the geparquinto phase iii neoadjuvant breast cancer trial |
| title_unstemmed | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1002/ijc.32163 |